Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0372 • ACR Convergence 2021
Impact of Gender and Age on Ankylosing Spondylitis Patient Profiles at Golimumab Initiation and 12-Month Outcomes
Ariel Masetto¹, Proton Rahman², Michelle Teo³, Pauline Boulos⁴, Emmanouil Rampakakis⁵, Meagan Rachich⁶, Allen Lehman⁶, Francois Nantel⁷ and Odalis Asin-Milan⁶, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ³Penticton Regional Hospital, Penticton, BC, Canada, ⁴., Hamilton, ON, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷., Montréal, QC, Canada
Background/Purpose: Gender and age have been previously identified as independent predictors of response to anti-TNFs. The aim of this analysis was to compare, between genders…
Abstract Number: 0829 • ACR Convergence 2021
Tapering and Withdrawal of Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Inflammatory Arthritis: A Systematic Review and Meta-Analyses of Randomised Trials
Line Uhrenholt¹, Robin Christensen², Wilfred K Dinesen³, Caroline Liboriussen³, Stine Andersen³, Lene Dreyer¹, Annette Schlemmer⁴, Ellen-Margrethe Hauge⁵, Conni Skrubbeltrang⁶ and Salome Kristensen¹, ¹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ²Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, ³Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁴Department of Rheumatology, Randers Regional Hospital, Randers, Denmark, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Medical Library, Aalborg University Hospital, Aalborg, Denmark
Background/Purpose: Tapering and withdrawal of biological or targeted synthetic disease-modifying antirheumatic drugs (bDMARDs or tsDMARDs) in patients with inflammatory arthritis (IA) in remission or low…
Abstract Number: 0918 • ACR Convergence 2021
Individual Components Contributing to the Achievement of Assessment in SpondyloArthritis International Society 40 Response in Biologic Naïve Patients with Radiographic Axial Spondyloarthritis: Results from the COAST V Trial
Denis Poddubnyy¹, Suzan Mansour Hussein Attar², Michael J. Nissen³, Erica Fillipi⁴, Hagen Russ⁴, Alper Erdogan⁴, Yves Schymura⁴, Soyi Liu-Leage⁵, Eduardo Collantes-Estevez⁶ and Francesco Ciccia⁷, ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²King Abdulaziz University, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ³Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁴Eli Lilly and Company Ltd., Indianapolis, IN, ⁵Eli Lilly and Company, Neuilly sur Seine, France, ⁶Department of Rheumatology, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain, ⁷University of Campania “Luigi Vanvitelli", Naples, Italy
Background/Purpose: Ixekizumab (IXE), an IL-17A antagonist, is effective in patients with radiographic axial spondyloarthritis (rad-axSpA). Assessment in SpondyloArthritis International Society (ASAS) 40 response – the…
Abstract Number: 1305 • ACR Convergence 2021
Undiagnosed Depression in Axial Spondyloarthropathy and the Negative Impact on Patient Outcomes: Results of a Screening Study
Sinead Maguire¹, Phil Gallagher² and Finbar (Barry) O'Shea¹, ¹St James's Hospital, Dublin, Ireland, ²St Vincent's Hospital, Dublin, Ireland
Background/Purpose: Previous research in axial spondyloarthropathy(axSpA) has shown this population to have a high prevalence of depression. This co-morbidity has been previously shown to impact…
Abstract Number: 0067 • ACR Convergence 2021
Mendelian Randomisation Analysis of Protein Quantitative Trait Loci with Ankylosing Spondylitis Reveals Causative Involvement of Key Effector Proteins and Pathways
Nicholas Harvey¹, Zhixiu Li², Jose Garrido-Mesa³, Jie Zheng⁴, Paul Wordsworth⁵, John Reveille⁶, Mario Falchi³, Niccolo Rossi³, Alessia Visconti³, David Evans⁷ and Matthew Brown³, ¹Molecular Genetics, London, United Kingdom, ²Queensland University of Technology, Brisbane, Australia, ³King's College London, London, United Kingdom, ⁴Bristol University, Bristol, United Kingdom, ⁵Oxford University, Oxford, United Kingdom, ⁶Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁷University of Queensland, Brisbane, Australia
Background/Purpose: Susceptibility to ankylosing spondylitis (AS) is known to be highly influenced by genetic factors, with heritability assessed in twins of >90%, with >115 genetic…
Abstract Number: 0374 • ACR Convergence 2021
Validation of the Ankylosing Spondylitis Disease Activity Score with a Quick Quantitative Creactiveprotein Assay (ASDAS-qCRP) in Patients with Axial Spondyloarthritis (axSpA): Aprospective, National, Multicenter Study
Fabian Proft¹, Julia Schally², Henning Christian Brandt³, Jan Brandt-Jrgens⁴, Gerd Burmester¹, Hildrun Haibel⁵, Henriette Käding², Kirsten Karberg⁶, Susanne Lüders⁷, Burkhard Muche², Mikhail Protopopov¹, Judith Rademacher¹, Valeria Rios Rodriguez¹, Murat Torgutalp¹, Maryna Verba⁸, Silke Zinke⁹ and Denis Poddubnyy¹⁰, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ³Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, ⁴Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁶Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ⁷Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ⁸Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁹Rheumapraxis Berlin, Berlin, Germany, ¹⁰Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: According to international recommendations, the Ankylosing Spondylitis Disease Activity Score (ASDAS) is the preferred score for assessing disease activity in axial spondyloarthritis (axSpA) [1].…
Abstract Number: 0838 • ACR Convergence 2021
Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans
Tawnie Braaten¹, shaobo Pei², Anitha Rathod², Gopi Penmetsa³, Kevin Douglas⁴, Jodi Walker⁴, Jerry Clewell⁵ and Jessica Walsh⁶, ¹Salt Lake City Veteran Affairs and University of Utah Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴AbbVie Inc., North Chicago, IL, ⁵Abbvie Inc, North Chicago, IL, ⁶Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: Non-treatment and treatment delays contribute to suboptimal symptom control and irreversible joint damage in patients with inflammatory arthritis (IA). This investigations objective was to…
Abstract Number: 0919 • ACR Convergence 2021
Ixekizumab Shows a Distinct Pattern of Pain Improvement Beyond Measurable Inflammation as Assessed by MRI or CRP or BASDAI Questions 5 & 6 in Patients with Ankylosing Spondylitis
Kurt de Vlam¹, Philip Conaghan², Philip Mease³, Proton Rahman⁴, Venkatesh Krishnan⁵, Rebecca Bolce⁵, David Sandoval Calderon⁵, So Young Park⁵, Gaia Gallo⁵ and Walter Maksymowych⁶, ¹University Hospitals Leuven, Leuven, Belgium, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology at the University of Alberta, Alberta, Canada
Background/Purpose: Ixekizumab (IXE) demonstrated rapid efficacy in patients (pts) with AS at week (W) 16 in the absence of elevated inflammation as measured by baseline…
Abstract Number: 1306 • ACR Convergence 2021
Clinical and Imaging Characteristics of Spondyloarthritis Among Crohn’s Disease Patients
Laarni Quimson¹, Nisa Oren², Catherine Burns³ and Reem Jan², ¹University of Chicago, Oak Park, IL, ²University of Chicago, Chicago, IL, ³Indiana University, Indianapolis, IN
Background/Purpose: Inflammatory bowel disease (IBD) affects up to 1.3% of the population and is associated with musculoskeletal manifestations including spondyloarthritis (SpA). Axial SpA (axSpA) is…
Abstract Number: 0068 • ACR Convergence 2021
Gut Bacteria Causing Ankylosing Spondylitis Identified Through Mendelian Randomization Studies
Nicholas Harvey¹, Jose Garrido-Mesa², Zhixiu Li³, David Evans⁴, Peter Sternes⁵ and Matthew Brown², ¹Molecular Genetics, London, United Kingdom, ²King's College London, London, United Kingdom, ³Queensland University of Technology, Brisbane, Australia, ⁴University of Queensland, Brisbane, Australia, ⁵Queensland University of Technology, Bisbane, Australia
Background/Purpose: There is strong evidence from animal models, human microbiome profiling studies, genetic analyses, and from the model of reactive arthritis, that AS is caused…
Abstract Number: 0382 • ACR Convergence 2021
Six-year Results from the Esperanza Cohort: Evaluation of Clinical Features, Disease Activity Measures and Treatment Aspects in Axial and Peripheral Early Spondyloarthritis
Carolina Tornero¹, Victoria Navarro-Compán², raquel almodovar³, Cristina fernández-Carballido⁴, Azucena Hernández⁵, Beatriz Joven-Ibáñez⁶, Xavier Juanola⁷, M.Lourdes Ladehesa-Pineda⁸, José Ramón maneiro⁹, Antoni Juan Mas¹⁰, carlos Montilla¹¹, Manuel J Moreno¹², Mireia moreno¹³, José A. pinto¹⁴, juan Carlos Quevedo¹⁵, José Rosas¹⁶, Teresa Ruiz¹⁷, Jesús Sanz¹⁸ and Eugenio De Miguel¹⁹, ¹University Hospital La Paz, Madrid, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Hospital Universitario Fundación de Alcorcón, Madrid, Spain, ⁴H. San Juan, Alicante, Alicante, Spain, ⁵Hospital Virgen de la Salud, Toledo, Spain, ⁶University Hospital 12 de Octubre, Madrid, Spain, ⁷Hospital Universitari de Bellvitge, Barcelona, Spain, ⁸Hospital Universitario Reina Sofía, Córdoba, Spain, ⁹Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain, ¹⁰Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ¹¹Hospital Universitario de Salamanca, Salamanca, Spain, ¹²Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ¹³Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí I3PT, Sabadell, Spain, ¹⁴Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain, ¹⁵Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶Hospital Marina Baixa, Villajoyosa, ¹⁷Hospital de Sierrallana, Servicio de Reumatología, Torrelavega, Spain, ¹⁸Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹⁹Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Esperanza was a multicenter national health program developed to facilitate an early diagnosis of patients with Spondyloarthritis (SpA) in Spain. The main objective of…
Abstract Number: 0897 • ACR Convergence 2021
Age-Stratified Trend of Spinal Radiographic Damage Progression in Patients with Ankylosing Spondylitis
Tae-Han Lee¹, Bon San Koo², Bora Nam³, Seunghun Lee⁴, Kyung Bin Joo⁴ and Tae-Hwan Kim³, ¹Keimyung University Dongsan Hospital, Daegu, Republic of Korea, ²Inje University Seoul Paik Hospital, Seoul, Republic of Korea, ³Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁴Hanyang University Hospital, Seoul, Republic of Korea
Background/Purpose: Previous studies investigating the course of spinal structural progression in patients with ankylosing spondylitis (AS) using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)…
Abstract Number: 0920 • ACR Convergence 2021
Influence of Baseline Demographics on Improvements in Disease Activity Measures in Patients with Ankylosing Spondylitis Receiving Upadacitinib: A Post Hoc Subgroup Analysis
Filip Van den Bosch¹, Denis Poddubnyy², Jayne Stigler³, Andrew Ostor⁴, Salvatore D'Angelo⁵, Victoria Navarro-Compán⁶, In-Ho Song³, Tianming Gao³, Fabiana Ganz³ and Lianne Gensler⁷, ¹Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ²Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ³AbbVie Inc., North Chicago, IL, ⁴Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁵Rheumatology Institute of Lucania (IReL) – Rheumatology Department of Lucania, “San Carlo” Hospital of Potenza and “Madonna delle Grazie” Hospital of Matera, Potenza, Italy, ⁶Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ⁷Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Upadacitinib (UPA), an oral Janus kinase inhibitor, has demonstrated efficacy and safety through 14 weeks in the SELECT-AXIS 1 study in biologic disease-modifying antirheumatic…
Abstract Number: 1314 • ACR Convergence 2021
Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis
Haluk Cinaklı¹, Elif Ediboglu¹, Eda Otman Akat², Dilek Solmaz³, Gulay Alp¹, Esra Erpek¹, Sercan Gücenmez⁴, Mustafa Ozmen⁴ and Servet Akar³, ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²katip çelebi, izmir, Turkey, ³Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ⁴katip çelebi university, izmir, Turkey
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease mainly affecting sacroiliac joints and spine. Peripheral arthritis, dactylitis and enthesitis may also occur. Acute…
Abstract Number: 0139 • ACR Convergence 2021
Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists in an Academic Health System: A Retrospective Study
Alexis Ogdie-Beatty¹, Marina Magrey², Robert Fitzsimmons¹, Shahrzad Abdollahi¹, Ana Biljan³, Christopher Saffore⁴ and Jessica Walsh⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH, ³Abbvie Inc., Chicago, IL, ⁴AbbVie, North Chicago, IL, ⁵Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: While recommendations for the treatment of ankylosing spondylitis (AS) are largely aligned across various guidelines,1,2 there remains variability in the treatment. Patients with inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].